Health Care · Surgical & Medical Instruments & Apparatus

LUCD Lucid Diagnostics Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 179901143 filings
Russell 2000

LUCD at a glance

Lucid Diagnostics Inc. (LUCD, SEC CIK 1799011) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as February 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Lucid Diagnostics Inc. (LUCD) reported revenue of $4.7 million (up 8.3% from FY2024) and a net loss of $58.0 million. Diluted EPS was -$0.69.
  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Lucid Diagnostics Inc. (LUCD) shares worth $18.1 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$4.7M
+8.3% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
21 funds
$18.1M · −1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $1.2M, flat versus $1.2M in Q3 2025
  • Gross margin negative 16.7% versus negative 41.7% YoY, based on revenue and cost of revenue
  • Sales and marketing worst-performing expense line: $5.3M, up from $4.3M YoY
  • Cash $18.0M at September 30, 2026; operating cash use $38.9M for nine months
  • Series C preferred offering generated $15.0M gross proceeds; going-concern doubt and recurring losses remain near-term headwinds

AI summary of the LUCD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Lucid Diagnostics announced fiscal quarter results for the period ended September 30, 2026
  • Business update included alongside the quarterly financial release

Item EX-99.1: Item EX-99.1

  • Nationwide Medicare reimbursement at $1,938.01 per EsoGuard test removes a major commercialization barrier
  • Record October volume exceeded 1,800 tests after 2,871 tests in 3Q26, signaling early acceleration but requiring revenue conversion
Filed Oct 22, 2026Full analysis →

Item 3.02: Unregistered Sales of Equity Securities

  • $15.0M gross proceeds from 15,000 Series C preferred shares, strengthening liquidity through accredited-investor financing
  • Initial conversion price $0.3519, creating substantial potential common-stock dilution subject to 4.99% holder and 19.99% Nasdaq limits

Item 3.03: Material Modification to Rights of Security Holders

  • Security-holder rights modification links to Item 3.02 and Item 5.03 disclosures
  • Investor impact depends on the financing terms and charter or bylaw changes described in those referenced sections

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Series C Certificate of Designation amended Lucid Diagnostics’ Delaware certificate of incorporation
  • Amendment creates or governs Series C preferred stock rights, as detailed under Item 3.02
Filed Oct 16, 2026Full analysis →

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Nasdaq deficiency: LUCD closing bid below $1 for 30 consecutive business days through October 9, 2026
  • Compliance deadline April 12, 2027, requiring a $1 bid price for 10 consecutive business days

AI summaries of LUCD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LUCD

Don't miss the next LUCD filing

  • Alerts as it files. A push when LUCD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LUCD, by share count.
  • Ask anything. An AI agent that reads every LUCD filing and answers with sources.

LUCD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MCGRATH DENNIS MAFeb 20, 2026-
Cox James LAFeb 20, 2026-
PALUMBO JOHN RAFeb 20, 2026-
White DebraAFeb 20, 2026-
Sparks Ronald MAFeb 20, 2026-
O'Neil ShaunAFeb 20, 2026-
SOKOLOV JACQUE JAFeb 20, 2026-
Aklog LishanAFeb 20, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$4.3M$4.7M
Operating Income-$48.5M-$46.1M-$49.6M
Net Income-$52.7M-$45.5M-$58.0M
Op. Margin--1059.6%-1054.8%
Net Margin--1047.6%-1232.7%
Balance Sheet
Total Assets$27.3M$30.7M$40.4M
Equity-$5.4M$10.9M
ROE--844.5%-530.4%
Per Share
EPS$-1.26$-1.05$-0.69
Cash Flow
Operating CF--$44.1M-$46.5M
CapEx-$296K$197K

Source: XBRL data in Lucid Diagnostics Inc. (LUCD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LUCD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LUCD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$18.1M
Q2 202622$25.7M
Q1 202622$17.2M
Q4 202519$15.4M
Q3 202516$12.0M
Q2 202516$12.0M
Q1 202512$3.0M
Q4 20245$592,000
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 133 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LUCD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
8-KOct 22, 2026Analysis-
8-KOct 16, 2026Analysis-
8-KSep 22, 2026Analysis-
8-KAug 13, 2026Analysis-
10-QAug 12, 2026Analysis
8-KJun 24, 2026Analysis-
8-KMay 14, 2026Analysis
10-QMay 13, 2026Analysis
8-KApr 24, 2026Analysis-
8-KApr 23, 2026Analysis-
8-KMar 26, 2026--
10-KMar 25, 2026-
4Feb 24, 2026--
4Feb 24, 2026--
4Feb 24, 2026--
4Feb 24, 2026--
4Feb 24, 2026--
4Feb 24, 2026--
4Feb 24, 2026--
4Feb 24, 2026--
4Feb 24, 2026--
10-QNov 12, 2025Analysis
10-QAug 12, 2025-

Related Health Care companies

All Health Care →

LUCD SEC filings: frequently asked questions

Which institutions hold LUCD stock?

As of September 30, 2026, the largest Lucid Diagnostics Inc. (LUCD) holders among the 13F filers tracked by SignalX were BlackRock ($6.3 million), Vanguard Capital Management LLC ($4.5 million), Wells Fargo & Co ($1.9 million), State Street Corp ($1.8 million), Northern Trust ($929,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LUCD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Lucid Diagnostics Inc. (LUCD) reported revenue of $4.7 million (up 8.3% from FY2024) and a net loss of $58.0 million. Diluted EPS was -$0.69. The figures come from the XBRL data in the 10-K.

What did LUCD report in its latest 8-K?

Lucid Diagnostics Inc. (LUCD) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Lucid Diagnostics announced fiscal quarter results for the period ended September 30, 2026.

What are the latest LUCD SEC filings?

Lucid Diagnostics Inc. (LUCD) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on February 24, 2026.

What is LUCD's SEC CIK number?

Lucid Diagnostics Inc. (LUCD)'s SEC Central Index Key (CIK) is 1799011. EDGAR lists every LUCD filing under that number.

Ask anything about LUCD

The research agent reads LUCD's filings, financials, insider trades and 13F holders, then answers with sources.